par Vanlaethem, Yves ;Sternon, Jacques
Référence Revue médicale de Bruxelles, 24, 1, page (42-46)
Publication Publié, 2003-02
Article révisé par les pairs
Résumé : Telithromycine is the first ketolide on the market. Its characteristics are the two sites fixation on the bacterial ribosomia and as a consequence a good activity on the majority of penicillin and macrolides resistant bacteria, included S. pneumonia and S. pyogenes. Telithromycine represents an alternative to βlactames and moxifloxacine to treat communautary pneumonia, bacterial pharyngoamygdalitis, suppurative sinusitis and bronchitis. There are nevertheless problems with drugs interactions and risk of resistance development.